v3.26.1
Asset Purchase and Merger Agreements - Urica Agreement with Crystalys Therapeutics, Inc. ("Crystalys") (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 31, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Business Combination [Line Items]            
Royalty revenue   $ 879 $ 1,404 $ 996 $ 1,404  
Urica            
Business Combination [Line Items]            
Percentage of equity to be held 35.00%          
Increase in fair value of investment due to anti-dilutive shares received       3,200    
Increase in fair value due to equity financing       8,600    
Royalty revenue   $ 10,700   $ 11,800    
Other income from reversal of repurchase option liability           $ 2,600
Urica | Asset Purchase, Royalty And Related Agreements With Crystalis            
Business Combination [Line Items]            
Consideration transferred $ 6,400          
Recorded accretion     $ (100)   $ 600  
Urica | Crystalys Therapeutics, Inc            
Business Combination [Line Items]            
Required minimum ownership (as a percent)   12.00%   12.00%    
Percentage of royalty on future net sales 3.00%          
Royalty revenue       $ 0    
Urica | Crystalys Therapeutics, Inc | Minimum            
Business Combination [Line Items]            
Required minimum ownership (as a percent) 15.00%